Hyperlipemia drugmakers face dilemma

It is a challenging time for domestic and foreign hyperlipemia drugmakers.

These companies face a bashing by from the government and outer negative factors – lowing price cut and failing to meet soaring raw material costs due to weaker Korean won value.

Pharmaceutical sources said most of these firms feel torn between steering away from the double woes amid a sharp economic contraction.
...